Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

[1]  C. Elmets,et al.  Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. , 2005, Vaccine.

[2]  J. Mascola,et al.  Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope , 2004, Journal of Virology.

[3]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[4]  M. Grubman,et al.  Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. , 2003, Vaccine.

[5]  G. Nabel,et al.  Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines , 2003, Journal of Virology.

[6]  S. Epstein.  Control of influenza virus infection by immunity to conserved viral features , 2003, Expert review of anti-infective therapy.

[7]  K. Elkins,et al.  Multiple T Cell Subsets Control Francisella tularensis LVS Intracellular Growth Without Stimulation Through Macrophage Interferon γ Receptors , 2003, The Journal of experimental medicine.

[8]  Y. Kawaoka,et al.  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. , 2003, Vaccine.

[9]  Qi Chen,et al.  Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. , 2003, Vaccine.

[10]  N. Cox,et al.  Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. , 2003, Virology.

[11]  B. Moss,et al.  Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting , 2003, Journal of Virology.

[12]  K. Subbarao,et al.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. , 2002, Emerging infectious diseases.

[13]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[14]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[15]  J. A. Misplon,et al.  Heterosubtypic Immunity to Influenza A Virus in Mice Lacking IgA, All Ig, NKT Cells, or γδ T Cells1 , 2001, The Journal of Immunology.

[16]  T. Tumpey,et al.  Mucosal Delivery of Inactivated Influenza Vaccine Induces B-Cell-Dependent Heterosubtypic Cross-Protection against Lethal Influenza A H5N1 Virus Infection , 2001, Journal of Virology.

[17]  W. Blackwelder,et al.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. , 2001, Vaccine.

[18]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[19]  R. Webster,et al.  Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. , 2000, Vaccine.

[20]  W Chen,et al.  Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. , 2000, Immunity.

[21]  J. Bennink,et al.  Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. , 2000, International immunology.

[22]  N. Cox,et al.  A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from Humans , 1999, Journal of Virology.

[23]  H. Goto,et al.  Biological Heterogeneity, Including Systemic Replication in Mice, of H5N1 Influenza A Virus Isolates from Humans in Hong Kong , 1999, Journal of Virology.

[24]  G. Nabel,et al.  Molecular Medicine © 1999 The Picower Institute Press Efficient Generation of Recombinant Adenoviral Vectors by Cre-lox Recombination In Vitro , 1999 .

[25]  J. Ulmer,et al.  Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA , 1998, Journal of Virology.

[26]  M. Eloit,et al.  Replication-defective adenovirus type 5 as an in vitro and in vivo gene transfer vector in chickens. , 1995, The Journal of general virology.

[27]  K. Mozdzanowska,et al.  Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. , 1994, Journal of immunology.

[28]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[29]  R. North,et al.  Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4- CD8- cells. , 1991, The Journal of infectious diseases.

[30]  W. Fitch,et al.  Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses. , 1989, The Journal of general virology.

[31]  E. Lennette,et al.  Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections , 1989 .

[32]  G. Quinnan,,et al.  Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines. , 1988, The Journal of general virology.

[33]  T Sonoguchi,et al.  Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. , 1985, The Journal of infectious diseases.

[34]  S. An,et al.  The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. , 1959, Bulletin of the World Health Organization.